Table 1.
Demographics and mean (of the three readers) hippocampal DGCL ratings for all patients (1–16) and controls (17–31) on a scale of 1 – 6.
| a Age/gender | a Disease duration | Medication | Mean DGCL rating | ||
|---|---|---|---|---|---|
| Right | Left | ||||
| 1 | 23/M | 3 | Risperidone | 2.3 | 2.7 |
| 2 | 26/M | 8 | Ziprasidone | 2.3 | 1.7 |
| 3 | 29/F | 8 | Aripiprazole, Bupropion, Fluphenazine | 4.3 | 4 |
| 4 | 29/M | 9 | Clomipramine, Clonazepam, Risperidone, | 4.0 | 5.7 |
| 5 | 29/F | 9 | Aripiprazole | 3.3 | 4.3 |
| 6 | 35/M | 6 | Risperidone | 2.3 | 3.0 |
| 7 | 42/F | 23 | Bupropion, Eszopiclone, Ziprasidone | 2.0 | 2.3 |
| 8 | 43/M | 18 | Halperidol, Quetiapine | 4.0 | 3.7 |
| 9 | 44/M | 26 | Clozapine, Valproic Acid | 3.0 | 4.7 |
| 10 | 44/F | 27 | Quetiapine | 2.3 | 2.3 |
| 11 | 49/F | 31 | Aripiprazole | 4.3 | 5.0 |
| 12 | 51/M | 31 | Risperidone | 1.7 | 2.3 |
| 13 | 51/F | 35 | - | 4.0 | 4.3 |
| 14 | 52/M | 32 | Citalopram | 3.0 | 2.7 |
| 15 | 52/M | 22 | Aripiprazole, Paroxetine, Trazadone, Valproic Acid | 5.0 | 4.3 |
| 16 | 53/M | 31 | Clozapine, Gabapentin, Venlafaxine | 2.7 | 3.3 |
| 17 | 21/F | - | - | 3.0 | 3.7 |
| 18 | 23/M | - | - | 4.0 | 3.3 |
| 19 | 27/F | - | - | 3.7 | 3.3 |
| 20 | 29/F | - | - | 2.7 | 3.3 |
| 21 | 31/F | - | - | 5.3 | 4.3 |
| 22 | 31/M | - | - | 3.0 | 2.7 |
| 23 | 34/F | - | - | 5.3 | 4.7 |
| 24 | 36/M | - | - | 2.3 | 4.0 |
| 25 | 37/F | - | - | 3.7 | 3.7 |
| 26 | 37/M | - | - | 3.7 | 4.0 |
| 27 | 38/M | - | - | 3.3 | 3.0 |
| 28 | 43/M | - | - | 5.7 | 5.7 |
| 29 | 46/M | - | - | 4.7 | 4.3 |
| 30 | 47/M | - | - | 5.0 | 3.3 |
| 31 | 55/F | - | - | 3.3 | 4.3 |
a
Years.